| Similar Articles |
|---|
 |
The Motley Fool
April 15, 2011
Brian Orelli |
Fewer Needle Pricks for the Europeans Amylin's once-weekly diabetes drug Bydureon gets a positive recommendation in Europe.   |
The Motley Fool
March 3, 2011
Brian D. Pacampara |
Amylin Pharmaceuticals Shares Plunged: What You Need to Know Shares of Amylin Pharmaceuticals plummeted more than 20% Thursday after its type 2 diabetes drug Bydureon failed to meet primary endpoints in a 26-week study. |
The Motley Fool
July 8, 2011
Luke Timmerman |
Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial What does this mean for the drug companies? |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
October 20, 2010
Brian Orelli |
There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon. |
The Motley Fool
July 22, 2010
Brian Orelli |
It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead. |
The Motley Fool
January 27, 2011
Brian Orelli |
Amylin Timeline Shortened -- Maybe Revenue down 6% year over year. Prescriptions of the company's top-selling drug, Byetta, down 5.9% quarter over quarter. Amylin Pharmaceuticals' fourth quarter wasn't pretty. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. |
The Motley Fool
December 9, 2008
Brian Orelli |
FDA Dashes Amylin Investors' Hopes Shareholders are still waiting to hear how much longer it'll be before Amylin and Eli Lilly can submit the marketing application for the once-weekly version of diabetes drug Byetta. |
The Motley Fool
December 12, 2008
Brian Orelli |
Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA. |
The Motley Fool
June 16, 2010
Brian Orelli |
A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug. |
The Motley Fool
June 18, 2010
Brian Orelli |
Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed. |
The Motley Fool
June 30, 2004
Alyce Lomax |
A Monster Drug for Lilly? The drug giant files a new drug application (NDA) for its experimental new drug for diabetics. |
The Motley Fool
March 5, 2008
Brian Orelli |
FDA (Indirectly) Thwacks Amylin The FDA's draft guidance puts a cloud of uncertainty over the makers of diabetes drugs. |
The Motley Fool
November 24, 2006
Brian Lawler |
Amylin Gets Past the Formalities Following a formal approval from the EU for Byetta, Amylin can get down to business. Investors, take note. |
The Motley Fool
October 2, 2007
Brian Orelli |
Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note. |
The Motley Fool
April 20, 2010
Brian Orelli |
Drug Sales Down! Should We Celebrate? Amylin won't have completed results for a trial comparing Bydureon to Victoza until next year. But until that data is in, it might not be as easy to get the patients back as Amylin is making it out to be. |
The Motley Fool
July 22, 2008
Brian Orelli |
Anemic Amylin's Signs of Recovery Sales of Amylin Pharmaceuticals' diabetes drug Byetta have slowed over the last few quarters, but the company seems to be turning things around. |
The Motley Fool
November 3, 2009
Brian Orelli |
Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend. |
The Motley Fool
August 27, 2008
Brian Orelli |
Amylin Answers, Investors Panic Amylin Pharmaceuticals' conference call about side effects of its diabetes treatment, Byetta, doesn't have the desired effect. |
The Motley Fool
March 3, 2011
Brian Orelli |
Amylin Comes Up Snake Eyes Amylin Pharmaceuticals and partners Eli Lilly and Alkermes announced results of their head-to-head clinical trial comparing Bydureon with Novo Nordisk's diabetes drug Victoza. |
The Motley Fool
June 24, 2008
Brian Orelli |
A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly. |
The Motley Fool
March 27, 2009
Brian Orelli |
The Skinny on a Triple-Decker Update Amylin's public relations department might need to go on a diet. |
The Motley Fool
July 8, 2011
Brian Orelli |
Let's Just Hope For No More FDA Surprises Despite the government's worries, Bydureon doesn't cause heart issues. |
The Motley Fool
April 17, 2009
Brian Orelli |
Cost-Cutting? Check. Increased Sales? Hmm ... Amylin has half the equation. Now it needs the other half. |
The Motley Fool
June 11, 2008
Brian Orelli |
Amylin's Down and Up on Diabetes Investors may be over-reacting to news both good and bad from Amylin Pharmaceuticals. |
The Motley Fool
September 9, 2008
Brian Orelli |
Drug Duo Combines Its Way Toward an Approval Bristol-Myers and AstraZeneca are trying to get their diabetes drug approved as a combination treatment. |
The Motley Fool
December 8, 2010
Brian Orelli |
Up 100% With Room to Fly Orexigen gets a positive FDA panel nod. |
The Motley Fool
November 9, 2011
Brian Orelli |
Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it |
The Motley Fool
July 22, 2009
Brian Orelli |
The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough? |
The Motley Fool
September 22, 2010
Brian Orelli |
Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
June 26, 2009
Brian Orelli |
Looking for a Sliver of the Me-Too Pie Another diabetes drug is close to hitting the market. |
The Motley Fool
November 24, 2010
Brian Orelli |
Profit From the United States of Diabetes Half the country could have an early form by 2020. |
The Motley Fool
December 7, 2007
Brian Orelli |
Amylin's Temporarily Worthless Label Expansion Amylin releases label expansion data that won't be useful for a few years. Investors, take note. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
April 22, 2008
Brian Orelli |
Amylin Treads Water One-drug wonders like Amylin Pharmaceuticals can't get away with stagnant growth. |
The Motley Fool
November 8, 2011
David Williamson |
Biotech Pops, Drops, and Break-Ups Highlighting the day's health-care stories critical to investors. |
The Motley Fool
October 21, 2011
Brian Orelli |
Full of News, but Worth a 15% Gain? Amylin serves up an appetizer. |
The Motley Fool
November 1, 2007
Brian Orelli |
Good News From Amylin Isn't Good Enough Investors aren't impressed by Amylin's extended-release version of Byetta, worrying that the drug may be reaching market saturation. |
The Motley Fool
April 8, 2009
Brian Orelli |
I'm Rich! I'm Ruined! Overreaction Equals Opportunity Knowing your company lets you judge when the market has overreacted. |
The Motley Fool
October 2, 2009
Brian Orelli |
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. |
The Motley Fool
October 19, 2006
Brian Lawler |
Amylin's One-Drug Wonder Unfortunately, with research and development costs growing to $54 million from $33 million last year, Amylin is still a few quarters away from profitability. Diabetes drug Byetta is set to boost Amylin's sales. Investors, take note. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
August 19, 2008
Brian Orelli |
Too Much Punishment for Amylin Several more pancreatitis cases cause Amylin Pharmaceuticals' investors to panic. |
The Motley Fool
June 9, 2008
Brian Lawler |
Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note. |
The Motley Fool
November 5, 2008
Brian Orelli |
A Byetta Beating The FDA gives Amylin and Alkermes a smack down, but neither company is knocked out yet. |
The Motley Fool
January 29, 2008
Brian Orelli |
No Weight Loss at Amylin Bulging costs related to its diabetes drug Byetta keep the drugmaker from showing a profit this quarter. |
The Motley Fool
September 30, 2011
Brian Orelli |
A Drug Market That's 366 Million Strong Diabetes drugs have potential. |
